NZ595011A - Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases - Google Patents

Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases

Info

Publication number
NZ595011A
NZ595011A NZ595011A NZ59501110A NZ595011A NZ 595011 A NZ595011 A NZ 595011A NZ 595011 A NZ595011 A NZ 595011A NZ 59501110 A NZ59501110 A NZ 59501110A NZ 595011 A NZ595011 A NZ 595011A
Authority
NZ
New Zealand
Prior art keywords
dkk
seq
amino sequence
antibodies
bind
Prior art date
Application number
NZ595011A
Other languages
English (en)
Inventor
Marcio Chedid
Ryan James Darling
Rachelle Jeanette Galvin
Barbara Anne Swanson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NZ595011A publication Critical patent/NZ595011A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ595011A 2009-04-10 2010-04-06 Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases NZ595011A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16841109P 2009-04-10 2009-04-10
PCT/US2010/030039 WO2010117980A1 (en) 2009-04-10 2010-04-06 Dkk-1 antibodies

Publications (1)

Publication Number Publication Date
NZ595011A true NZ595011A (en) 2013-05-31

Family

ID=42199718

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ595011A NZ595011A (en) 2009-04-10 2010-04-06 Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases

Country Status (30)

Country Link
US (1) US8148498B2 (https=)
EP (3) EP2417158B9 (https=)
JP (1) JP5759977B2 (https=)
KR (3) KR20110124364A (https=)
CN (1) CN102388065B (https=)
AR (1) AR075989A1 (https=)
AU (1) AU2010234611B2 (https=)
BR (1) BRPI1014157B1 (https=)
CA (1) CA2758252C (https=)
CY (3) CY1119399T1 (https=)
DK (3) DK2930184T3 (https=)
EA (1) EA021401B1 (https=)
ES (3) ES2887176T3 (https=)
HR (3) HRP20171400T1 (https=)
HU (3) HUE055376T2 (https=)
IL (1) IL214845A (https=)
LT (3) LT2930184T (https=)
ME (2) ME02798B (https=)
MX (1) MX2011010707A (https=)
NZ (1) NZ595011A (https=)
PL (3) PL2930184T3 (https=)
PT (3) PT2930184T (https=)
RS (3) RS58612B1 (https=)
SG (1) SG175244A1 (https=)
SI (3) SI2930184T1 (https=)
TR (1) TR201907261T4 (https=)
TW (1) TWI546079B (https=)
UA (1) UA103916C2 (https=)
WO (1) WO2010117980A1 (https=)
ZA (1) ZA201107256B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120475A1 (es) 2009-05-12 2012-05-05 Pfizer Anticuerpos especificos para dkk-1
CN111961134B (zh) 2012-12-10 2024-04-05 比奥根Ma公司 抗血液树突细胞抗原2抗体及其用途
AU2016263030A1 (en) * 2015-05-18 2017-10-12 Eli Lilly And Company Anti-Dkk-1-anti-RANKL bispecific antibody compounds
CA2996059A1 (en) * 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
KR102701695B1 (ko) 2016-10-26 2024-08-30 리프 테라퓨틱스 인코포레이티드 항-dkk-1 항체를 사용하여 암을 치료하기 위한 바이오마커로서의 베타-카테닌의 용도
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
MX2020013172A (es) 2018-06-08 2021-03-29 Alector Llc Anticuerpos anti-siglec-7 y sus metodos de uso.
AU2019301160A1 (en) * 2018-07-11 2021-02-25 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered Fc-antigen binding domain constructs targeted to CTLA-4
CN112121147B (zh) * 2019-06-24 2023-07-04 中国人民解放军海军特色医学中心 多肽在治疗或预防骨髓瘤药物中的应用、多肽、核酸、药物及重组表达载体
BR112022004851A2 (pt) * 2019-09-19 2022-08-23 Leap Therapeutics Inc Uso de inibidores de dkk-1 para tratar câncer
EP4061419A1 (en) 2019-11-22 2022-09-28 Leap Therapeutics, Inc. Methods of treating cancer using dkk-1-inhibitors
KR102494042B1 (ko) 2020-11-20 2023-02-07 주식회사 하울바이오 인간모유두세포의 성장을 촉진하는 항-dkk-1 항체 및 이의 용도
CN112592402B (zh) * 2020-12-02 2022-04-26 杭州奕安济世生物药业有限公司 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途
IL304927A (en) * 2021-02-05 2023-10-01 Omeros Corp A biomarker for assessing the risk of developing acute COVID-19 and post-acute COVID-19
WO2023039249A1 (en) 2021-09-10 2023-03-16 Leap Therapeutics, Inc. Combination therapy
EP4471056A4 (en) * 2022-01-28 2026-02-18 Shanghai Junshi Biosciences Co Ltd Anti-DKK1 antibodies, pharmaceutical composition and associated uses
KR20250057775A (ko) 2022-07-12 2025-04-29 리프 테라퓨틱스 인코포레이티드 조합 요법
CN116589590B (zh) * 2023-03-21 2024-03-26 浙江大学 一种特异性抗异菌脲的单克隆抗体及其重组表达质粒

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU7137398A (en) 1997-04-16 1998-11-11 Millennium Pharmaceuticals, Inc. Crsp protein (cysteine-rich secreted proteins), nucleic acid molecules encoding them and uses therefor
DE19747418C1 (de) * 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US7446181B2 (en) * 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
JP3868740B2 (ja) 1998-03-10 2007-01-17 ジェネンテック・インコーポレーテッド 新規なポリペプチド及びそれをコードする核酸
CA2399776A1 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
IL158750A0 (en) 2001-05-17 2004-05-12 Genome Therapeutics Corp Reagents and methods for modulating dkk-mediated interactions
US20040038860A1 (en) * 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
US7371736B2 (en) * 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
US7308364B2 (en) * 2001-11-07 2007-12-11 The University Of Arkansas For Medical Sciences Diagnosis of multiple myeloma on gene expression profiling
JP2005512557A (ja) 2001-11-07 2005-05-12 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ アーカンソー 遺伝子発現プロファイリングに基づく多発性骨髄腫の診断、予後、および治療標的候補の同定
US7642238B2 (en) * 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US20050084494A1 (en) * 2003-05-21 2005-04-21 Darwin Prockop Inhibitors of Dkk-1
EP1636388A2 (en) 2003-06-06 2006-03-22 Wyeth Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
MX2007001221A (es) 2004-08-04 2007-03-23 Amgen Inc Anticuerpos para proteina dickkopf-1 (dkk-1).
AR060017A1 (es) * 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
CN101641373B (zh) * 2007-02-08 2015-02-11 默沙东公司 Dkk-1的特异性抗体
CN102421798A (zh) * 2009-05-07 2012-04-18 诺瓦提斯公司 与dickkopf-1或dickkopf-4或两者的结合分子的组合物及使用方法

Also Published As

Publication number Publication date
SG175244A1 (en) 2011-12-29
EP3514173B8 (en) 2021-08-04
CY1119399T1 (el) 2018-02-14
CA2758252C (en) 2015-02-24
KR20140090273A (ko) 2014-07-16
HUE043904T2 (hu) 2019-09-30
PL2417158T3 (pl) 2017-12-29
PT2930184T (pt) 2019-06-17
RS62214B1 (sr) 2021-09-30
RS56505B1 (sr) 2018-02-28
CY1121637T1 (el) 2020-07-31
TR201907261T4 (tr) 2019-06-21
HUE034625T2 (en) 2018-02-28
EP2417158B9 (en) 2017-12-06
HUE055376T2 (hu) 2021-11-29
JP5759977B2 (ja) 2015-08-05
DK2930184T3 (da) 2019-05-13
ME03378B (me) 2020-01-20
KR20110124364A (ko) 2011-11-16
SI2930184T1 (sl) 2019-06-28
WO2010117980A1 (en) 2010-10-14
UA103916C2 (xx) 2013-12-10
LT3514173T (lt) 2021-09-10
HRP20190643T1 (hr) 2019-05-31
KR20140033523A (ko) 2014-03-18
LT2930184T (lt) 2019-05-10
KR101461362B1 (ko) 2014-11-13
CN102388065B (zh) 2014-09-03
CA2758252A1 (en) 2010-10-14
PT2417158T (pt) 2017-10-23
ES2644244T3 (es) 2017-11-28
EA201171237A1 (ru) 2012-04-30
HRP20171400T1 (hr) 2017-11-03
SI2417158T1 (sl) 2017-10-30
DK2417158T3 (en) 2017-10-16
BRPI1014157A2 (pt) 2020-09-29
TWI546079B (zh) 2016-08-21
EP3514173B1 (en) 2021-06-23
AU2010234611B2 (en) 2013-02-07
US8148498B2 (en) 2012-04-03
EP3514173A1 (en) 2019-07-24
RS58612B1 (sr) 2019-05-31
US20100260754A1 (en) 2010-10-14
DK3514173T3 (da) 2021-08-02
ZA201107256B (en) 2013-03-27
AU2010234611A1 (en) 2011-10-20
IL214845A (en) 2016-06-30
EA021401B1 (ru) 2015-06-30
ES2887176T3 (es) 2021-12-22
EP2417158A1 (en) 2012-02-15
CN102388065A (zh) 2012-03-21
ME02798B (me) 2018-01-20
EP2417158B1 (en) 2017-08-02
IL214845A0 (en) 2011-11-30
ES2728911T3 (es) 2019-10-29
HRP20211343T1 (hr) 2021-11-26
CY1124412T1 (el) 2022-07-22
MX2011010707A (es) 2012-02-28
PT3514173T (pt) 2021-08-16
PL2930184T3 (pl) 2019-10-31
DK2417158T4 (da) 2018-01-29
JP2012523417A (ja) 2012-10-04
PL3514173T3 (pl) 2022-01-17
AR075989A1 (es) 2011-05-11
LT2417158T (lt) 2017-10-10
SI3514173T1 (sl) 2021-09-30
TW201100101A (en) 2011-01-01
EP2930184B1 (en) 2019-03-27
EP2930184A1 (en) 2015-10-14
BRPI1014157B1 (pt) 2022-01-18

Similar Documents

Publication Publication Date Title
NZ595011A (en) Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
NZ603607A (en) Cgrp antibodies
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
NZ628943A (en) Human antibodies to clostridium difficile toxins
NZ609619A (en) Novel egfr-binding molecules and immunoconjugates thereof
NZ608660A (en) Anti-cd48 antibodies and uses thereof
NZ714313A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
NZ598202A (en) High affinity human antibodies to human angiopoietin-2
PE20090161A1 (es) Anticuerpos monoclonales anti cxcl13
NZ592436A (en) Treatment with anti-alpha2 integrin antibodies
NZ598391A (en) Anti-hepcidin antibodies and uses thereof
NZ603529A (en) Antibodies to human gdf8
NZ626665A (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
JP2013542194A5 (https=)
NZ602020A (en) Anti-cd40 antibodies
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
RU2018119165A (ru) Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение
MX2011008843A (es) Anticuerpos humanizados que se unen a cd19 y sus usos.
PE20221337A1 (es) Anticuerpos trem2 y usos de estos
NZ583605A (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
NZ610734A (en) Human antibodies to the glucagon receptor
TW200720289A (en) Antibodies against CCR5 and uses thereof
NZ623347A (en) Novel anti-dr5 antibody
NZ590863A (en) Anti-hepcidin-25 selective antibodies and uses thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 06 APR 2017 BY THOMSON REUTERS

Effective date: 20140320

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2018 BY THOMSON REUTERS

Effective date: 20170322

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2019 BY THOMSON REUTERS

Effective date: 20180321

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2020 BY THOMSON REUTERS

Effective date: 20190319

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2021 BY THOMSON REUTERS

Effective date: 20200317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2022 BY ANAQUA SERVICES

Effective date: 20210323

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2023 BY ANAQUA SERVICES

Effective date: 20220323

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2024 BY ANAQUA SERVICES

Effective date: 20230321

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2025 BY ANAQUA SERVICES

Effective date: 20240320

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2026 BY ANAQUA SERVICES

Effective date: 20250319

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2027 BY ANAQUA SERVICES

Effective date: 20260320